Abstract
Three U.S. National Cancer Institute cooperative group randomized phase 3 trials have demonstrated that the intraperitoneal delivery of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves survival compared to the administration of all agents by the intravenous route. As use of intraperitoneal chemotherapy requires additional resources and expertise beyond that associated with routine intravenous treatment, and unique side effects may be observed (e.g., catheter malfunction, intra-abdominal infection), some have questioned the utility of this approach, despite the documented survival advantage. This review outlines the data supporting intraperitoneal delivery in ovarian cancer, discusses strategies to safely and effectively employ regional therapy, and highlights areas where future trials are required to optimize this novel method for treatment of this malignancy.
Keywords: paclitaxel, Cisplatin, toxicity profile, randomized trials, Southwest Oncology Group
Reviews on Recent Clinical Trials
Title: Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Volume: 2 Issue: 3
Author(s): Maurie Markman
Affiliation:
Keywords: paclitaxel, Cisplatin, toxicity profile, randomized trials, Southwest Oncology Group
Abstract: Three U.S. National Cancer Institute cooperative group randomized phase 3 trials have demonstrated that the intraperitoneal delivery of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves survival compared to the administration of all agents by the intravenous route. As use of intraperitoneal chemotherapy requires additional resources and expertise beyond that associated with routine intravenous treatment, and unique side effects may be observed (e.g., catheter malfunction, intra-abdominal infection), some have questioned the utility of this approach, despite the documented survival advantage. This review outlines the data supporting intraperitoneal delivery in ovarian cancer, discusses strategies to safely and effectively employ regional therapy, and highlights areas where future trials are required to optimize this novel method for treatment of this malignancy.
Export Options
About this article
Cite this article as:
Markman Maurie, Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions, Reviews on Recent Clinical Trials 2007; 2 (3) . https://dx.doi.org/10.2174/157488707781662698
DOI https://dx.doi.org/10.2174/157488707781662698 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Synthesis, Antitubercular and Anticancer Activities of p-nitrophenylethylenediamine- Derived Schiff Bases
Medicinal Chemistry Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine
Current Immunology Reviews (Discontinued) Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Synthesis and Anti-tumor Activity Evaluation of Gallic Acid-mangiferin Hybrid Molecule
Medicinal Chemistry Hybrid Compounds as Multitarget Directed Anticancer Agents
Current Topics in Medicinal Chemistry Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability
Anti-Cancer Agents in Medicinal Chemistry Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Supramolecular Nanomedicine - An Overview
Current Drug Targets New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Involvement of MicroRNA Mir15a in Control of Human Ovarian Granulosa Cell Proliferation, Apoptosis, Steroidogenesis, and Response to FSH
MicroRNA